 |
|
A novel mechanism of action for anti-tumor agent, CA4P
October 07, 2005Anti-angiogenic agents have been successful in the clinic for blocking the growth of solid tumors. However, these agents used in combination with chemotherapy have improved the survival of patients with cancers by only several months. Therefore, identification of unrecognized angiogenic pathways that selectively support tumor neo-vessel assembly will increase the efficacy of anti-angiogenic or anti-vascular therapy.
The prototypical vascular targeting agent combretastatin A4 phosphate (CA4P) exerts its anti-angiogenic effect by targeting unstable budding tumor neo-vessels. CA4P is currently being studied in clinical trials in oncology.
In a paper appearing online on October 6 in advance of print publication of the November issue of the Journal of Clinical Investigation, Shahin Rafii and colleagues from Cornell University provide important mechanistic data demonstrating how CA4P has anti-tumor and anti-angiogenic activity.
The authors find that CA4P selectively targets endothelial cells (flat-shaped cells that make up the inside of blood vessels) but not smooth muscle cells (cells which surround most blood vessels), and induces regression of unstable, newly formed vessels by disruption of Vascular Endothelial-cadherin (VE-cadherin) signaling. VE-cadherin is a protein found at the junctions of overlapping regions of endothelial cells and plays a key role in many aspects of vascular function including, endothelial cell survival, cell migration, cell proliferation and assembly into vessel-like structures.
Dissecting the mechanism whereby CA4P exerts its anti-vascular effect will open up new avenues of research to selectively target tumor neo-vessels and increase the therapeutic window of anti-angiogenic agents.
Journal of Clinical Investigation
The authors find that CA4P selectively targets endothelial cells (flat-shaped cells that make up the inside of blood vessels) but not smooth muscle cells (cells which surround most blood vessels), and induces regression of unstable, newly formed vessels by disruption of Vascular Endothelial-cadherin (VE-cadherin) signaling. VE-cadherin is a protein found at the junctions of overlapping regions of endothelial cells and plays a key role in many aspects of vascular function including, endothelial cell survival, cell migration, cell proliferation and assembly into vessel-like structures.
Dissecting the mechanism whereby CA4P exerts its anti-vascular effect will open up new avenues of research to selectively target tumor neo-vessels and increase the therapeutic window of anti-angiogenic agents.
Journal of Clinical Investigation
Anti-tumor Agent Current Events and Anti-tumor Agent News RSSUC Santa Barbara chemist goes nano with CoQ10
If Bruce Lipshutz has his way, you may soon be buying bottles of water brimming with the life-sustaining coenzyme CoQ10 at your local Costco.
Metformin increases pathologic complete response rates in breast cancer patients with diabetes
Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing pathologic complete response rates in diabetic women with early stage breast cancer who took the drug during chemotherapy prior to having surgery, paving the way for further research of the drug as a potential cancer therapy, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Enzyme may hold key to improved targeting of cancer-fighting drugs
A critical enzyme used to prepare a powerful cancer-killing agent may be able to help drug makers better target the cells the natural product attacks, according to findings published in the May 23 edition of the Journal of Biological Chemistry.
Dehydrated tomatoes show promise for preventing prostate cancer
New research suggests that the form of tomato product one eats could be the key to unlocking its prostate cancer-fighting potential, according to a report in the June 1 issue of Cancer Research, a journal of the American Association for Cancer Research.
Skin flaps deliver cancer-fighting therapy, ASPS study reveals
Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume.
Chinese medicinal compound stops formation of cysts in polycystic kidney disease in lab
Using a compound from a centuries-old Chinese traditional medicine, Yale University researcher Dr. Craig Crews has been able to prevent the formation of kidney-destroying cysts in a mouse model of polycystic kidney disease.
Mining for gems in the fungal genome
Ever since penicillin, a byproduct of a fungal mold, was discovered in 1929, scientists have scrutinized fungi for other breakthrough drugs.
Interesting lead in the treatment of Ewing`s sarcoma
Research scientists at INSERM, CNRS and the Institut Curie, in collaboration with physicians, have used a mouse model to demonstrate the efficacy of an innovative therapeutic approach to Ewing`s sarcoma: the combination of human interferon (alpha or beta) and a common anti-tumor agent, ifosfamide. Their results were published in the November 2002 issue of Oncogene and point to an interesting lead in the development of a less intensive and more effective therapeutic strategy for Ewing`s sarcoma, a severe bone cancer occurring children and adolescents. Before holding out hope, particularly to patients with metastatic disease, whose survival rate is poor, these findings must be confirmed in cl
More Anti-tumor Agent Current Events and Anti-tumor Agent News Articles
 |
The Epothilones: An Outstanding Family of Anti-Tumor Agents: From Soil to the Clinic (Fortschritte der Chemie organischer Naturstoffe / Progress in the Chemistry of Organic Natural Products) by Johann H. Mulzer (Editor), A. Douglas Kinghorn (Editor), Karl-Heinz Altmann (Editor), Gerhard Höfle (Editor), Rolf Müller (Editor), Kathrin Prantz (Editor) Epothilones have received unusual attention over the past ten years. They are novel antitumor drugs which very much like their predecessor paclitaxel (Taxol) act via microtubule stabilization. In comparison to paclitaxel and a number of alternative drugs with a similar mode of bioaction (e.g. laulimalide, eleutherobin, peluroside, discodermolide) the epothilones have significant advantages, above all very high activity in the nanomolar range and low susceptibility towards multidrug resistance. Epothilone B and several derivatives thereof are in phase I-III clinical trials; one of them (ixabepilone, BMS) is already on the market, others are supposed to appear on the market in the near future. All naturally occurring epothilones have been isolated from Sorangium cellulosum; their antitumor... |
 |
Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents (Crc Enzyme Inhibitors) by Paul J. Smith (Editor), Eddy W. Yue (Editor) One of the few books to cover all aspects of cyclin-dependent kinases (CDKs), Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents provides an overview of CDKs as molecular and functional entities, their involvement in different disease processes, and their potential for pharmacological modulation. With contributions from the top international researchers in the field, the book takes a contemporary approach to study the importance of rational drug design and knowledge-based therapeutics in relation to CDKs. The first two sections of the book discuss the integration of cell cycle control pathways, opportunities for targeting, targets of inhibitors, and the evaluation of CDK inhibitors, exploring topics such as the in vivo function of CDKs in normal homeostasisand tumor... |
|
The synthesis of a possible anti-tumor agent by Nicholas George Malafis (Author) | |
|
Natural anti-tumor agents from the Senecioneae by Leon Zalkow (Author) | |
|
The anti-tumor agent of aplopappus heterophyllus by Leon Zalkow (Author) | |
|
Clinical Evaluation of Anti-Tumor Therapy (Developments in Oncology) by Franco M. Muggia (Editor), Marcel Rozencweig (Editor) | |
|
Camptotheca Acuminata Decaisne, XI Shu, a Promising Anti-Tumor and Anti-Viral Tree for the Twenty-First Century (Chinese Happytree : a Promising Anti-Tumor and Anti-Viral Tree for the 21st Century) by Shiyou Li (Author), Kent T. Adair (Author) | |
|
Anti-tumor necrosis factor drugs may raise lymphoma risk in arthritis patients.(Rheumatology): An article from: Internal Medicine News by Patrice Wendling (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on June 15, 2005. The length of the article is 484 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Anti-tumor necrosis factor drugs may raise lymphoma risk in arthritis patients.(Rheumatology) Author: Patrice Wendling Publication: Internal Medicine News (Magazine/Journal) Date: June 15, 2005 Publisher: Thomson Gale Volume: 38 Issue: 12 Page: 37(1) Distributed by Thomson... | |
|
Anti-TNF agents for the treatment of psoriasis.(ORIGINAL ARTICLES)(tumor necrosis factor)(Clinical report): An article from: Journal of Drugs in Dermatology by Leon H. Kircik (Author), James Q. Del Rosso (Author) This digital document is an article from Journal of Drugs in Dermatology, published by Journal of Drugs in Dermatology, Inc. on June 1, 2009. The length of the article is 10859 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Anti-TNF agents for the treatment of psoriasis.(ORIGINAL ARTICLES)(tumor necrosis factor)(Clinical report) Author: Leon H. Kircik Publication: Journal of Drugs in Dermatology (Magazine/Journal) Date: June 1, 2009 Publisher: Journal of Drugs in Dermatology, Inc. Volume: 8 Issue: 6 Page: 546(14) Article Type: Clinical report Distributed by Gale, a part of... | |
|
Anti-TNF agents safe and effective in 'real-life' trials.(Rheumatology)(anti-tumor necrosis factor therapy): An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on August 15, 2004. The length of the article is 657 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Anti-TNF agents safe and effective in 'real-life' trials.(Rheumatology)(anti-tumor necrosis factor therapy) Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: August 15, 2004 Publisher: International Medical News Group Volume: 37 Issue: 16 Page: 28(1) Distributed by Thomson... |
| © 2009 BrightSurf.com |